Download MendeleyDiscovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine beta-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
Wu, Y.J., Guernon, J., Shi, J., Marcin, L., Higgins, M., Rajamani, R., Muckelbauer, J., Lewis, H., Chang, C., Camac, D., Toyn, J.H., Ahlijanian, M.K., Albright, C.F., Macor, J.E., Thompson, L.A.(2016) J Med Chem 59: 8593-8600
- PubMed: 27559936
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01012
- Primary Citation of Related Structures:
5KQF, 5KR8 - PubMed Abstract:
Truncation of the S3 substituent of the biaryl aminothiazine 2, a potent BACE1 inhibitor, led to a low molecular weight aminothiazine 5 with moderate activity. Despite its moderate activity, compound 5 demonstrated significant brain Aβ reduction in rodents. The metabolic instability of 5 was overcome by the replacement of the 6-dimethylisoxazole, a metabolic soft spot, with a pyrimidine ring. Thus, truncation of the S3 substituent represents a viable approach to the discovery of orally bioavailable, brain-penetrant BACE1 inhibitors.
Organizational Affiliation:
Research and Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06492-7660, United States.
